Background-The decision on whether to implant a drug-eluting or bare-metal stent during percutaneous coronary intervention (PCI) depends in part on the perceived likelihood of the patient developing late stent thrombosis. Noncardiac surgery and bleeding are associated with discontinuation of dual antiplatelet therapy and with increased stent thrombosis. We assessed the incidence of and predictors for subsequent noncardiac surgery and bleeding episodes in patients who had undergone PCI. Methods and Results-Hospital discharge coding data were used to identify all adult patients undergoing public hospital PCI in New Zealand from 1996 to 2001. Hospital admissions during the ensuing 5 years were analyzed for noncardiac surgery and bleeding episodes. Eleven thousand one hundred fifty-one patients (age, 62Ϯ11 years; 30% women) underwent PCI, mainly for an acute coronary syndrome (73%). During the 5-year follow-up, 26% of the population underwent at least 1 noncardiac surgical procedure (23% orthopedic, 20% abdominal, 12% urologic, 10% vascular, 35% others) and 8.6% had at least 1 bleeding episode either requiring or occurring during hospitalization. Of those, half were gastrointestinal, and one quarter of bleeding events required blood transfusion.
D rug-eluting stents (DES) are associated with a late stent thrombosis rate of Ϸ0.6% per annum. 1 Dual antiplatelet therapy with aspirin and clopidogrel is recommended for at least 12 months after DES implantation compared with 4 weeks after a bare-metal stent (BMS) is deployed. 2 Although this recommendation is not based on randomized trial data, earlier cessation of antiplatelet therapy has been associated with increased stent thrombosis. 3 Noncardiac surgery and significant bleeding have direct prothrombotic effects and indirectly predispose to stent thrombosis through the discontinuation of dual antiplatelet therapy. In those patients at increased risk for these events after percutaneous coronary intervention (PCI), a BMS may be preferred over a DES. 4, 5 
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Knowledge of the likelihood of a patient requiring noncardiac surgery or developing significant bleeding after PCI should allow the interventional cardiologist to better "fit the stent to the patient" and may reduce the incidence of late stent thrombosis. This study evaluated patients undergoing PCI to assess the subsequent rate of noncardiac surgery or bleeding requiring hospital admission. We also determined clinical predictors for these events.
Methods
All adult patients (age, Ն16 years) undergoing PCI in New Zealand public hospitals and surviving to hospital discharge, between January 1996 and December 2001, were identified from hospital discharge Diagnosis-Related Groups (DRG) codes. The DRG codes, taken from the World Health Organization International Classification of Diseases Versions 9 and 10 (http://www.who.int), included all coronary angioplasty with or without stent implantation undertaken at the 5 PCI centers in New Zealand: Green Lane, Waikato, Wellington, Christchurch, and Dunedin hospitals. During the time period of patient accrual, DES were not available; BMS were used in 70% to 90% of procedures, with the remainder having balloon angioplasty alone. 6 All patients were given aspirin indefinitely and a thienopyridine, either ticlopidine or clopidogrel, for 2 to 3 weeks.
The index PCI procedure was defined as the first PCI performed in each patient in the 6-year period of interest. The New Zealand hospital events dataset was available from January 1989 to December 2006. To maintain uniformity across the analysis, information on each patient was collected from 6 years before the index PCI for baseline characteristics and history, and up to 5 years after the index PCI for subsequent clinical events.
Baseline demographic and clinical characteristics were obtained using DRG codes from both the index PCI admission and all previous admissions to public hospitals, including PCI and non-PCI centers, within 6 years before the index PCI. Data for presenting diagnosis of stable angina, acute myocardial infarction, cardiac failure, and cardiogenic shock were collected from the index PCI admission. History of each individual patient included previous PCI, previous coronary artery bypass grafting (CABG), history of heart failure, hypertension, diabetes, atrial fibrillation, hypercholesterolaemia, smoking status, peripheral vascular disease, chronic renal impairment, hemodialysis, peritoneal dialysis, cerebrovascular accident, transient ischemic attack, solid organ cancer, osteoarthritis, osteoporosis, rheumatoid arthritis, prostatic hypertrophy, and peptic ulcer disease. All previous inpatient noncardiac surgical procedures were recorded; specific subgroups included were lower limb vascular operations, carotid endarterectomy, large joint replacement surgeries, and transurethral resection of the prostate. All previous admissions related to bleeding were recorded and categorized into gastrointestinal, urologic, neurologic, gynecologic, and ear-nose-throat hemorrhage. Bleeding severity was not categorized in the DRG codes.
DRG codes from subsequent hospital admissions were used to determine the occurrence of clinical events of interest during the 5-year follow-up for each patient. These included all inpatient noncardiac surgical procedures, bleeding episodes requiring hospitalization with or without blood transfusion, myocardial infarction, congestive heart failure, repeat PCI, or CABG. An inpatient noncardiac surgical event was defined as any surgical operation requiring overnight hospital stay in a New Zealand public hospital, with the exclusion of CABG, which was considered as a separate outcome event. Heart valve operations without accompanying CABG were included as "noncardiac surgeries." Day-stay procedures were not included as an outcome event.
The New Zealand hospital events dataset provided complete follow-up of all public hospital admissions on every subject in the cohort. Records were censored if a subject died during the 5-year follow-up period. Events occurring in private hospitals or outside New Zealand were not captured with this dataset.
Statistical Analysis
Results are reported as mean (ϮSD) for continuous variables and counts (in percentages) for categorical variables. Two-tailed tests were used in all analyses, and a PϽ0.05 was considered statistically significant. Univariate and multiple variable Cox regression analyses were performed to identify significant pre-PCI risk predictors of post-PCI noncardiac surgery and bleeding episodes. Hazard ratios (HRs) with 95% CIs for each pre-PCI risk factor are reported. Risk predictors with PϽ0.15 in the univariate analysis were included in multiple variable models to obtain adjusted P values. Because of the large number of explanatory variables analyzed and because many are likely to be strongly correlated, classification tree analysis (R function RPART) 7 was used as an exploratory data analysis tool to identify the subgroups of patients at greatest risk of post-PCI noncardiac surgery or bleeding episodes. Risk factors affecting Ͼ100 patients were fitted in the tree analysis. R function complexity plots were used to visualize the cross-validation. Based on the complexity plots, cost-complexity parameter cp values were chosen to determine the simplest tree with the smallest relative error (cpϭ0.003 was chosen for noncardiac surgery, and cpϭ0.002 was chosen for bleeding episodes).
2 test for trend was applied to compare the annual incidence of events. The cumulative incidences of noncardiac surgery and of major bleeding episodes were estimated with Kaplan-Meier curves. Statistical analysis was performed with SAS statistical software (release 9.1, SAS Institute Inc, Cary, NC) and R software (version 2.4.1, R Foundation for Statistical Computing, Vienna, Austria).
The authors had full access to the data and take responsibility for its integrity. The study was approved by the local ethics committee. 
Results

Baseline Characteristics
The clinical details and baseline characteristics of 11 151 patients who underwent PCI from January 1996 to December 2001 are outlined in Table 1 . At the time of the index PCI procedure, patients were ages 62Ϯ11 years (range, 16 to 93 years); 30% were women. The number of PCI procedures performed annually increased from 1249 in 1996 to 2599 in 2001. The most common clinical indication for PCI was an acute coronary syndrome, in 73% of patients. Cardiogenic shock was present in 1.3% of patients undergoing PCI. The prevalence of the usual risk factors for ischemic heart disease and other concomitant conditions is listed in Table 1 . Chronic renal impairment was found in 3.3% of the patients, with 0.4% on hemodialysis and 0.3% on peritoneal dialysis. Previous PCI and CABG had been undertaken in 4% and 3% of patients, respectively. Before the index PCI procedure, 22% of the patients had had 1 or more previous noncardiac surgical procedures, and 4% of patients had had 1 or more previous admissions for bleeding.
Events During Follow-Up
During the 5 years after the index PCI procedure, 1260 patients (11.2%) died. Repeat PCI was undertaken in 2155 patients (19.3%), at 1.2Ϯ1.4 years after the index PCI (18% within the first 6 weeks). Patients with repeat procedures had 1.3Ϯ0.8 further PCI. CABG was performed in 720 patients (6.5%), 1.3Ϯ1.4 years after the index PCI.
Two thousand nine hundred patients (26%) underwent 1 or more noncardiac surgical procedures; of those who had surgery, there was an average of 1.7Ϯ1.3 procedures. Over the same period, 959 patients (8.6%) had 1 or more hospital admissions because of bleeding, with 1.4Ϯ1.0 episodes per patient in those with bleeding. The noncardiac operations were orthopedic (23%), abdominal (20%), urologic (12%), plastic and dermatologic (12%), vascular (10%), and others (23%) (Figure 1 ). Gastrointestinal bleeding accounted for half of all patients who had a hospital admission for bleeding ( Figure 2) . A blood transfusion was required in 25% of bleeding episodes. The cumulative occurrence of noncardiac surgery and bleeding admissions during the 5-year follow-up is shown in Figure 3 .
The 6-month occurrence of noncardiac surgery and bleeding was 5.1% and 2.1%, respectively, whereas at 12 months, rates were 8.6% and 3.0%, respectively. The annual incidence of both clinical events did not change significantly during the 5 years of follow-up (Pϭ0.13).
Predictors for Post-PCI Noncardiac Surgery
Increasing patient age was a strong predictor of the need for post-PCI noncardiac surgery ( Figure 4A ). For each 10-year increase in age, there was a 1.3-fold increase in the incidence of post-PCI noncardiac surgery (PϽ0.0001). Women were 1.2 times more likely than men to require noncardiac surgery post-PCI (PϽ0.0001).
Previous noncardiac surgery was significantly associated with post-PCI noncardiac surgery (HR, 2.0) ( Table 2) . Patients with previous urologic and plastic procedures were particularly likely to require further surgery. Other conditions significantly associated with post-PCI noncardiac surgery are shown in Table 2 . Of note, chronic renal impairment (HR, 2.4), hemodialysis (HR, 3.9), and peritoneal dialysis (HR, 4.3) all strongly predicted post-PCI noncardiac surgery. Other risk predictors with a HR Ͼ2.0 included peripheral vascular disease, osteoarthritis, rheumatoid arthritis, prostatic hypertrophy, and a history of solid organ tumor. Traditional risk factors for atherosclerosis, such as hypertension, hypercholesterolemia, diabetes, and smoking, did not predict an increased need for future noncardiac surgery; hypercholesterolemia was associated with a lower risk of post-PCI noncardiac surgery (HR, 0.8).
Predictors for Post-PCI Bleeding Admissions
Increasing patient age and nonwhite ethnicity were significantly associated with post-PCI bleeding events ( Figure 4B ). For each 10-year increase in age, there was a 1.5-fold increase in the risk of bleeding post-PCI (PϽ0.0001). Whites had a lower risk of post-PCI bleeding than those from other ethnic groups (HR, 0.8).
Patients who had had a previous admission for bleeding had a 3-fold increase in readmission post-PCI for bleeding (Table 3) . Chronic renal impairment (HR, 2.9), hemodialysis (HR, 2.7), and peritoneal dialysis (HR, 3.6) were significantly associated with post-PCI bleeding. Other significant risk predictors included a history of solid organ tumor (HR, 2.1) and cerebrovascular disease (HR, 2.0). 
Classification Tree Analysis of At-Risk Patient Groups
Because of the heterogeneous nature of the study population, classification tree analysis was performed to identify specific subgroups with a high probability of having post-PCI noncardiac surgery or bleeding events. Figures 5 and 6 are the classification tree diagrams for post-PCI noncardiac surgery and bleeding admissions, respectively. Three subgroups of patients with a high likelihood of requiring noncardiac surgery were patients older than 65 years with osteoarthritis (52%, 217 of 413); patients older than 65 years without osteoarthritis but with previous urologic surgery (52%, 150 of 285); and patients younger than 65 years who had had previous vascular surgery (45%, 72 of 159). Two subgroups of patients with a high rate of post-PCI bleeding were those older than 65 years with previous bleeding (23%, 66 of 279) and those older than 65 years without a history of bleeding but with chronic renal impairment (22%, 47 of 209).
When events limited to the first 12 months of follow-up were analyzed, 3 subgroups of patients at risk of early noncardiac surgery were those older than 65 years with a history of solid tumor (22%, 85 of 391), those older than 65 years without a history of solid tumor but with chronic renal impairment (23%, 52 of 229), and those younger than 65 years with chronic renal impairment (32%, 35 of 111). Patients at risk for post-PCI bleeding within 12 months were those with a history of bleeding (9%, 43 of 478).
Discussion
To our knowledge, this is the first systematic assessment of the incidence of and predictors for patients requiring noncardiac surgery or having a bleeding episode after a PCI procedure. By 5 years, 1 in 4 patients will require noncardiac surgery, and 1 in 12 will have an episode of bleeding requiring hospitalization. In some subgroups, this risk is as high as 50% for noncardiac surgery and 20% for bleeding events. Previous retrospective studies evaluating perioperative cardiac events in patients undergoing noncardiac surgery post-PCI give widely varying estimates of the rate of noncardiac surgery. In one study, 5% of patients underwent noncardiac surgery by 1 year, 8 and in another 34% had undergone surgery by 2 years. 9 Late stent thrombosis occurs with all currently available DES. Reendothelialization up to 2 years after DES implantation is often incomplete, whereas with BMS there is usually complete coverage by 3 months. 10 Apart from a direct toxic effect of the antiproliferative drug, a late hypersensitivity reaction to the drug or the polymer coating may also occur. Other factors predisposing to stent thrombosis include inadequate stent expansion or stent-wall apposition 12 and a reduced antiplatelet response to aspirin and/or clopidogrel. 13 Early discontinuation of antiplatelet treatment because of poor patient compliance, for noncardiac surgery or for bleeding is associated with an increased likelihood of stent thrombosis. 14 -16 Noncardiac surgery carries an increased risk of mortality or major adverse cardiovascular events if undertaken in the first few weeks after angioplasty or stent deployment. 8, 9, [17] [18] [19] [20] The 2 strongest risk predictors are the perioperative discontinuation of antiplatelet therapy 9, 19 and the time interval between PCI and noncardiac surgery. After BMS deployment, the risk is greatly reduced after 4 to 6 weeks. 8, [17] [18] [19] [20] The optimal delay before undertaking noncardiac surgery after DES implantation is uncertain. In the study by Schouten et al, 9 the incidence of major adverse cardiovascular events was significantly higher if noncardiac surgery was performed within 1 History of previous bleeding 287 (4) 176 (6) 1.6 (1.4 to 1.9) Ͻ0.0001 Ͼ0.9
*Univariate Cox proportional hazards regression. †Multiple variable Cox proportional hazard regression. Adjusted P values are multivariable-adjusted P values. ‡In multivariable analysis, hemodialysis, peritoneal dialysis, and specific surgical procedures were not included because of too few patients in these categories and their overlapping with chronic renal impairment and subcategories of surgery.
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Noncardiac Surgery and Bleeding After Stentingmonth of BMS, 3 months of sirolimus DES, and 6 months of paclitaxel DES deployment. Clinicians should carefully consider patient-and lesionrelated factors when deciding whether to implant a DES or BMS. 4 Although planned noncardiac surgery soon after stent deployment is a relative contraindication for DES, the need for subsequent noncardiac surgery is often unknown at the time of PCI. In each patient, the incremental benefit of a DES over a BMS in avoiding restenosis must be weighed against the increased risk of late stent thrombosis with DES. Our study aids estimation of the latter risk, before PCI, by identifying clinically useful predictors of patients at higher risk of needing noncardiac surgery or having a bleeding episode.
Increasing age, as expected, has a significant impact on the occurrence of both noncardiac surgery and bleeding episodes. Previous noncardiac surgery and bleeding also usefully predicted subsequent surgery and bleeding, with HRs of 2.0 and 3.0, respectively. This study clearly highlights the major impact renal dysfunction has on events after PCI. Chronic renal impairment, with or without dialysis, was a strong predictor of both noncardiac surgery and bleeding post-PCI. Overall, more than 1 in 5 required noncardiac surgery within 12 months, and in those Ͼ65 years with renal impairment, more than 1 in 5 had an admission for bleeding within 5 years of their PCI procedure. Renal failure is commonly associated with diabetes; renal failure and diabetes are the 2 strongest patientrelated predictors of restenosis after BMS deployment. 21, 22 Taking these findings together, there are significant limitations with using either BMS or DES for PCI in patients with renal failure.
Univariate analysis revealed many other predictors associated with noncardiac surgery or bleeding. Classification tree analysis was a very useful way of identifying the most important predictors, which included age, previous bleeding, and some subgroups of previous noncardiac surgery. The simplified tree analysis presented here only included the most important predictors, rather than all those found to be significant in multivariable analysis.
During the time period covered by the study, DES were not used, and thienopyridine treatment was funded in New Zealand for only 3 weeks post-PCI. Because almost no patients were given extended dual antiplatelet therapy, the incidence of bleeding in our cohort represents that in a population with coronary disease taking aspirin alone. The bleeding rate with the currently used, extended dual antiplatelet regimen would be higher; for example, in the CURE trial patients given clopidogrel for 3 to 12 months with aspirin had a 1% absolute increase in the incidence of major bleeding compared with aspirin alone. 23 
Study Limitations
There are inherent limitations to retrospective studies, which rely on hospital discharge coding. The quality of the analyzed data depends on the accuracy and completeness of the clinical coding in each hospital. Discrete procedures, such as PCI and noncardiac surgery, are likely to be coded more accurately than other data, such as comorbidities. For clinical variables, such as chronic renal impairment and peripheral vascular disease, it is not possible to distinguish the severity of the condition from DRG coding. It is likely that more patients were included from the severe than the mild end of the disease spectrum because of coding bias in discharge documentation.
Individual patient data, which were not available from this dataset, included characteristics of the target lesion, 
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the type of stents deployed, antiplatelet therapy duration and compliance (including perioperative continuation or discontinuation), concurrent anticoagulation with warfarin, and surgical details, such as indication, urgency, and procedure duration. The study assessed public hospital discharge data only. Approximately 32% of the New Zealand population have health insurance, providing partial or complete reimbursement for private hospital elective surgical procedures. In 1998, 28% of PCI procedures were undertaken in private hospitals. 6 Although patients undergoing private hospital PCI were excluded from this study, some patients having acute or semiacute public hospital PCI will subsequently have had private elective noncardiac surgery. In other words, this analysis will underestimate the true rate of noncardiac surgery. On the other hand, the incidence of bleeding is likely to be more accurate as most of these patients present acutely and are cared for in public hospitals.
Medical practice in New Zealand is similar to that of the United Kingdom and Western Europe. Rates of some surgical procedures are higher in the United States than elsewhere, and so this study may underestimate US rates of noncardiac surgery post-PCI.
Summary
Noncardiac surgery is commonly needed in the 5 years after PCI, with readily identified cohorts at particularly increased risk. Bleeding is less frequent, but also increased in some patient subgroups. These data should aid decision making with regard to the use of BMS or DES during PCI.
